Advertisement
Advertisement

CRVS

CRVS logo

Corvus Pharmaceuticals, Inc.

20.68
USD
Sponsored
-0.26
-1.25%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

20.73

+0.05
+0.25%

CRVS Earnings Reports

Positive Surprise Ratio

CRVS beat 22 of 39 last estimates.

56%

Next Report

Date of Next Report
Mar 23, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.13
Implied change from Q3 25 (Revenue/ EPS)
--
/
+8.33%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-27.78%

Corvus Pharmaceuticals, Inc. earnings per share and revenue

On Nov 04, 2025, CRVS reported earnings of -0.12 USD per share (EPS) for Q3 25, beating the estimate of -0.13 USD, resulting in a 11.83% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.44% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of -0.13 USD, with revenue projected to reach -- USD, implying an increase of 8.33% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Corvus Pharmaceuticals, Inc. reported EPS of -$0.12, beating estimates by 11.83%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.44%, changed from $7.64 before the earnings release to $7.53 the day after.
The next earning report is scheduled for Mar 23, 2026.
Based on 9 analysts, Corvus Pharmaceuticals, Inc. is expected to report EPS of -$0.13 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement